Prognostic Models for HCC Based on Tumor Micronecrosis

Zhejiang University765 enrolled

Overview

The heterogeneity of hepatocellular carcinoma (HCC) leads to the unsatisfying predicting performance of current staging systems. HCC patients with pathological tumor micronecrosis have immunosuppressive microenvironment. We aimed to develop novel prognostic models by integrating micronecrosis to more precisely predict the survival of HCC patients after hepatectomy.

Study Type

OBSERVATIONAL

Enrollment

765

Conditions

Hepatocellular Carcinoma

Interventions

observing whether HCC patients having tumor micronecrosisOTHER

whether HCC patients having tumor micronecrosis or not

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. pathologically diagnosed as HCC; 2. curative hepatectomy with R0 resection; 3. conserved liver function with Child Pugh class A or B Exclusion Criteria: 1. with macrovascular invasion or extrahepatic metastasis; 2. receiving other anti-tumor treatments such as TACE or systemic drugs; 3. with other primary cancers; 4. incomplete follow-up data; 5. without sufficient formalin-fixed, paraffin-embedded (FFPE) specimens for micronecrosis evaluation

Locations (1)

the First Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

the Harrell concordance index (C-index)

Time frame: Up to 5 years

Secondary Outcomes

the time-dependent area under the receiver operating characteristic curve(tdAUROC)

Time frame: Up to 5 years

Central Contacts

Tingbo Liang, PhD

CONTACT

liangtingbo@zju.edu.cn

Qi Zhang, MD

CONTACT

13819137113 qi.zhang@zju.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.